- Company
- OTC pain reliever market grows surges, Tylenol up by 30%
- by Kim, Jin-Gu Sep 7, 2020 06:12am
- The OTC pain reliever market was yet again dominated by Tylenol and Geworin in the first half of this year. Compared to the first half of last year, specifically, Tylenol’s sales have surged 30 percent. Geworin, EZN6 and Tak-sen followed the market leader on the leader board and generated the highest six-month sales on the record. ◆
- Company
- Hanmi·Chong Kun Dang, leading the erectile dysfunction tx
- by Chon, Seung-Hyun Sep 4, 2020 06:53am
- The growth of the domestic erectile dysfunction treatment market has slowed. In the aftermath of COVID-19, the market size has decreased from last year for the first or second consecutive quarter. Generics by Hanmi and Chong Kun Dang are leading the market. According to IQVIA, a drug research institute on the 3rd, the market for erectile dys
- Company
- Keytruda coverage expansion plan back to MSD for revision
- by Eo, Yun-Ho Sep 4, 2020 06:53am
- Regarding the Keytruda coverage expansion, the South Korean authority passed the ball back to MSD Korea. The pharmaceutical industry sources reported Health Insurance Review and Assessment Service (HIRA) informed MSD on Sept. 2 about PD-1 inhibitor Keytruda’s (pembrolizumab) financial burden reduction plan the Cancer Deliberation Commi
- Company
- Celebrex barrier still too high for NSAID Acelex
- by Nho, Byung Chul Sep 4, 2020 06:52am
- The 22nd Korean-made novel drug (Bio-venture No. 1) and a nonsteroidal anti-inflammatory drug (NSAID) for arthritis Acelex (polmacoxib) seems to be stuck in a box pattern, struggling to narrow the sales gap with its biggest competitor Celebrex (celecoxib). IQVIA data found Acelex has generated 598 million won, 4.01 billion won, 4.78 bill
- Company
- Galderma Korea appoints Younhee Kim as the new CEO
- by Eo, Yun-Ho Sep 3, 2020 12:55pm
- Galderma Korea has appointed Younhee Kim, former general manager of the Medical Solution Division, as the new CEO. According to related industries, CEO Kim started official business as the official president on the October 1st. Rene Wipperich, former CEO of Galderma's Korean subsidiary for two years from September 2018, has been confirmed
- Company
- Sales of immunotherapy for Cancer are ↑18 times in 4 years
- by An, Kyung-Jin Sep 2, 2020 06:19am
- Immunotherapy for Cancer is expanding rapidly in the domestic pharmaceutical market. The domestic immune checkpoint inhibitor market started with Yervoy (Ipilimumab), Keytruda (Pembrolizumab), and Opdivo (Nivolumab), and generics such as Tecentriq (Atezolizumab) and Imfinzi (Durvalumab) were added one after another, sales increased by 18 t
- Company
- AZ Korea Director Chon as a new Country President Indonesia
- by Eo, Yun-Ho Sep 2, 2020 06:18am
- Chon Sewhan, a director at AstraZeneca Korea, has been promoted as a Country President at PT. AstraZeneca Indonesia The industry sources reported the current Cardiovascular, Renal and Metabolic Diseases (CVRM) Business Unit Director, Chon Sewhan, has been appointed as a Country President Indonesia as of Sept. 1. Started off his career
- Company
- Forxiga by AstraZeneca appeals against Dong-A ST
- by Kim, Jin-Gu Sep 2, 2020 06:18am
- AstraZeneca, which failed in the first round of the patent dispute over the SGLT-2 inhibitor-based diabetes treatment, Forxiga (Dapagliflozin), launched a counterattack against Dong-A ST. It disagrees with the trial decision of the Patent Tribunal, who sided with the generic company, and filed a lawsuit to the Patent Court of Korea to canc
- Company
- Indication of Alunbrig expanded as ALK-positive lung cancer
- by Sep 2, 2020 06:18am
- The indication has been expanded as the first line treatment of Takeda Pharmaceutical Korea's lung cancer treatment, Alunbrig. Takeda Pharmaceutical Korea (CEO Moon Hee-seok) announced on the 28th that The MFDS approved Alunbriq (Brigatinib), an anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer drug, to expand its indica
- Company
- Now, a transition of power in the contraceptive market
- by Sep 1, 2020 06:13am
- The domestic over-the-counter (OTC) pre-contraceptive market, which was almost monopolized by imported finished products, is showing mixed trend. Sales of top-tier products such as Myvlar have been sold out for a long period of time, resulting in a sharp decrease in sales, and recently released products are fiercely competing, causing changes.
